Dominique Costagliola,Francoise Brun-VÉZinet and Victor Degruttola Respond

Brun-Vézinet F. , Costagliola D. , Ait Khaled M. , Calvez V. , Clavel F. , Clotet B. , Haubrich R. , Kempf D. , King M. , Kuritzkes D. , Lanier R. , Miller M. , Miller V. , Phillips A. , Pillay D. , Schapiro J. , Scott J. , Shafer R. , Zazzi M. , Zolopa A. , & DeGrutolla V. Clinically validated genotype analysis: guiding principles and statistical concerns. Antiviral Therapy 2004; 9: 465–478.

Masquelier B. , Tamalet C. , Montes B. , Descamps D. , Peytavin G. , Bocket L. , Wirden M. , Izopet J. , Schneider V. , Ferre V. , Ruffault A. , Palmer P. , Trylesinsky A. , Miller M. , Brun-Vézinet F. , Costagliola D. , & the ANRS AC11 resistance group. Genotypic determinants of the virological response to tenofovir DF in NRTI-experienced patients. Antiviral Therapy 2004; 9: 315–323.

Sauerbrei W. , & Schumacher M. A bootstrap resampling procedure for model building: application to the Cox regression model. Statistics in Medicine 1992; 11: 2093–2109.

Cabrera C. , Cozzi-Lepri A. , Phillips A.N. , Loveday C. , Kirk O. , Ait-Khaled M. , Reiss P. , Kjoer J. , Ledergerber B. , Lundgren J.D. , Clotet B. , & Ruiz L. on behalf of the EuroSIDA Study Group. Baseline resistance and virological outcome in patients with virological failure who start a regimen containing abacavir: EuroSIDA study. Antiviral Therapy 2004; 9: 787–800.